aβ42 elisa kit (Cusabio)
Structured Review
Aβ42 Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/a%CE%B242+elisa+kit/Human+amyloid+beta+peptide+1-42%2CA%CE%B21-42+ELISA+Kit/pm41126442-262-10-14
Average 93 stars, based on 33 article reviews
Images
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Neuroprotective Effect of Ligustilide through Induction of α-Secretase Processing of Both APP and Klotho in a Mouse Model of Alzheimer’s Disease Article Snippet: .. The soluble and insoluble Aβ levels in all samples were determined using the commercially available mouse Aβ40 and Article Title: Astaxanthin Improved the Cognitive Deficits in APP/PS1 Transgenic Mice Via Selective Activation of mTOR. Article Snippet: .. Astaxanthin (Ast) is an effective neuroprotective and antioxidant compound Article Title: Modulating Amyloid Pathology-Neural Hyperexcitability Crosstalk for Alzheimer's Disease Therapy. Article Snippet: Current therapies for Alzheimer’s disease (AD) primarily target amyloid-β (Aβ) pathology using monoclonal antibodies, yet their limited efficacy partly results from unintended exacerbation of neural hyperexcitability.. This highlights a critical but underappreciated link between Aβ clearance and neuronal network dysfunction.. Here, we designed R@AClipo, a nanotherapeutic platform that codelivers the TREM2 agonist peptide COG1410 and the glutamate modulator riluzole via Angiopep-2−modified liposomes capable of crossing the blood−brain barrier. Concentration Assay:Article Title: Astaxanthin Improved the Cognitive Deficits in APP/PS1 Transgenic Mice Via Selective Activation of mTOR. Article Snippet: .. Astaxanthin (Ast) is an effective neuroprotective and antioxidant compound Article Title: Modulating Amyloid Pathology-Neural Hyperexcitability Crosstalk for Alzheimer's Disease Therapy. Article Snippet: Current therapies for Alzheimer’s disease (AD) primarily target amyloid-β (Aβ) pathology using monoclonal antibodies, yet their limited efficacy partly results from unintended exacerbation of neural hyperexcitability.. This highlights a critical but underappreciated link between Aβ clearance and neuronal network dysfunction.. Here, we designed R@AClipo, a nanotherapeutic platform that codelivers the TREM2 agonist peptide COG1410 and the glutamate modulator riluzole via Angiopep-2−modified liposomes capable of crossing the blood−brain barrier. |

